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Anhydrous copper(II) chloride (97%, Aldrich), lithium powder from granulated lithium 
(Chemetall),
[1]
 DTBB (4,4'-di-tert-butylbiphenyl, Aldrich), TBHP (5–6 M in decane or 
70 wt.% in water, Aldrich) and sodium Y zeolite (Aldrich) were commercially 
available. N,N-Dimethylaniline (Carlo Erba) was distilled before use. All other starting 
materials and reagents were commercially available of the best grade (Aldrich, Acros, 
Alfa Aesar) and were used without further purification. THF was dried in a Sharlab PS-
400-3MD solvent purification system using an alumina column. All reactions were 
carried out on a multireactor apparatus using the corresponding reactor tubes. Melting 
points were obtained with a Reichert Thermovar apparatus and are uncorrected. Optical 
rotations were measured using a Perkin-Elmer 341 polarimeter with a thermally 
jacketted 5 cm cell at approximately 20 ºC. Concentrations (c) are given in g/100 ml and 






. NMR spectra were recorded on Bruker 




NMR; 75 and 101 MHz 
for 
13
C NMR); chemical shifts are given in ( ) parts per million and coupling constants 
(J) in Hertz. Infrared analysis was performed with a Jasco 4100LE (Pike MIRacle ATR) 
spectrophotometer; wavenumbers ( ˜) are given in cm–1. Mass spectra (EI) were 
obtained at 70 eV on an Agilent 5973 spectrometer; fragment ions in m/z with relative 
intensities (%) in parentheses. HRMS analyses were also carried out in the electron 
impact mode (EI) at 70 eV on a Finnigan MAT95S spectrometer. Elemental analyses 
were performed on a Leco Micro TruSpec CHNS microanalyzer. The purity of volatile 
compounds and the chromatographic analyses (GLC) were determined with an Agilent 
6890N instrument equipped with a flame ionization detector and an HP-5MS 30 m 
capillary column (0.32 mm diameter, 0.25 m film thickness), using nitrogen (2 
mL/min) as carrier gas, Tinjector = 270 ºC, Tcolumn = 60 ºC (3 min) and 60–270 ºC (15 
ºC/min); retention times (tr) are given in min. Analytical thin-layer chromatography 
(TLC) was carried out on ALUGRAM
®
 Xtra SIL G UV254 aluminium sheets. 
Preparative thin-layer chromatography was carried on laboratory-made TLC glass plates 
with silica gel 60 PF254 (Merck). Column chromatography was performed using silica 
gel 60 of 40–60 microns (hexane/EtOAc as eluent). The tests for acetone determination 






Typical procedure for the preparation of CuNPs/ZY (Method A) 
Anhydrous copper(II) chloride (135 mg, 1.0 mmol) was dissolved in dry THF or water 
(15 mL) and sodium Y zeolite (1.28 g) was added to the resulting solution. The mixture 
was stirred in the presence (for THF) or absence (for water) of argon overnight, 
followed by filtration and washing with THF or water (20 mL), and drying under 
vacuum (12 h). 
 
Typical procedure for the preparation of CuNPs/ZY (Method B) 
Anhydrous copper(II) chloride (135 mg, 1.0 mmol) was added to a suspension of 
lithium powder (14 mg, 2.0 mmol) and 4,4'-di-tert-butylbiphenyl (DTBB, 27 mg, 0.1 
mmol) in dry THF (2 mL) at room temperature under an argon atmosphere. The 
reaction mixture, which was initially dark blue, rapidly changed to black, indicating that 
the suspension of copper nanoparticles was formed. This suspension was diluted with 
THF (18 mL) followed by the addition of sodium Y zeolite (1.28 g). The resulting 
mixture was stirred for 1 h at room temperature, filtered, and the solid successively 
washed with MeOH (5 mL) and THF (20 mL), and dried under vacuum (5 h). 
 
Typical procedure for the preparation of CuNPs/ZY (Method C) 
Following the impregnation method A, the resulting solid was added to a suspension of 
lithium powder (14 mg, 2.0 mmol) and 4,4'-di-tert-butylbiphenyl (DTBB, 27 mg, 0.1 
mmol) in THF (2 mL) at room temperature under an argon atmosphere. The resulting 
mixture was stirred for 1 h at room temperature, filtered, and the solid successively 
washed with MeOH (5 mL), THF (20 mL) and dried under vacuum (12 h). 
 
General procedure for the CDC of tertiary amines and terminal alkynes catalyzed 
by CuNPs/ZY 
The amine (1.0 mmol), the alkyne (1.0 mmol) and t-BuOOH-H2O (1.2 mmol) were 
added to a reactor tube containing CuNPs/ZY (50 mg, 1.5 mol%) under air. The 
reaction mixture was warmed to 70 ºC and stirred at that temperature for 15–20 h. The 
resulting mixture was diluted with EtOAc (15 mL), filtered through Celite and subjected 
to column chromatography (silica gel, hexane/EtOAc) or distillation (3ba) to give the 
pure propargylamines 3. The catalyst could be recovered by diluting the reaction crude 
with EtOAc (15 mL), followed by centrifugation (2500 rpm, 15 min), catalyst 
separation and washing (EtOAc, 15 mL), and final drying under vacuum (5 h). 
4 
 





oil (217 mg, 98%); Rf 0.63 (hexane/EtOAc, 9:1); tr 15.05; 
1
H 
RMN (300 MHz, CDCl3) δ 7.38–7.26 (m, 7H), 6.93–6.90 (m, 
2H), 6.81 (tt, J 7.4, 1.0, 1H), 4.26 (s, 2H), 3.03 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 
149.3, 131.7, 129.1, 128.2, 128.1, 123.2, 118.2, 114.4, 85.0, 84.1, 43.3, 38.7; IR (neat) 
ν˜ 3068, 3026, 2883, 2808, 1598, 1577, 1503, 1489, 1453, 1442, 1359, 1335, 1240, 
1196, 1112, 1030, 995, 922, 750, 715, 688; MS (70 eV) m/z (%) 222 (M
+
+1, 16), 221 
(M
+





Orange solid (205 mg, 87%); m.p. 91–92 ºC; tr 15.81; Rf 0.66 
(hexane/EtOAc, 9:1); 
1
H NMR (400 MHZ, CDCl3) δ 7.29–
7.25 (m, 4H), 7.06 (d, J 7.9, 2H), 6.91 (dd, J 8.8, 0.9, 2H), 6.82–6.78 (m, 1H), 4.25 (s, 
2H), 3.02 (s, 3H), 2.31 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 149.5, 138.3, 132.5, 
131.8, 129.2, 129.1, 120.1, 118.2, 114.5, 84.3, 43.5, 38.8, 21.6; IR (neat) ν˜ 3063, 3030, 
2921, 2870, 2812, 2228, 1598, 1504, 1453, 1334, 1238, 1199, 1010, 1034, 995, 922, 
815, 750, 689, 664; MS (70 eV) m/z (%) 236 (M
+
+1, 11), 235 (M
+
, 65), 234 (52), 144 





 Yellow solid (226 mg, 90%); m.p. 
68–69 ºC; tr 16.84; Rf 0.51 (hexane/EtOAc, 9:1); 
1
H NMR 
(400 MHz, CDCl3) δ 7.31–7.26 (m, 4H), 6.91 (d, J 8.0, 2H), 6.82–6.78 (m, 3H), 4.24 (s, 
2H), 3.78 (s, 3H), 3.03 (s, 3H); 
13
C NMR (101 MHZ, CDCl3) δ 159.5, 149.5, 133.3, 
129.2, 118.2,115.2, 114.5, 113.9, 84.1, 83.6, 55.4, 43.5, 38.8; IR (neat) ν˜ 3068, 3042, 
3009, 2958, 2824, 2224, 1598, 1570, 1505, 1495, 1462, 1452, 1439, 1368, 1319, 1291, 
1267, 1246, 1234, 1204, 1194, 1183, 1168, 1105, 1029, 1012, 999, 984, 974, 960, 916, 
872, 834, 815, 801, 753, 692, 678, 642; MS (70 eV) m/z (%) 251 (M
+
, 28), 250 (13), 





yl}benzoate (3ad). Yellow solid (204 mg, 73%); m.p. 
86–87 ºC; tr 17.94; Rf 0.51 (hexane/EtOAc, 9:1); 
1
H 
NMR (300 MHz, CDCl3) δ 7.95–7.91 (m, 2H), 7.43–7.39 (m, 2H), 7.31–7.25 (m, 2H), 
6.92–6.89 (m, 2H), 6.82 (tt, J 7.5, 1.0, 1H), 4.28 (s, 2H), 3.90 (s, 3H), 3.04 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 166.7, 149.3, 131.8, 129.6, 129.5, 129.3, 127.9, 118.4, 114.5, 
88.4, 83.6, 52.3, 43.5, 38.9; IR (neat) ν˜ 3068, 3017, 2951, 1712, 1600, 1504, 1434, 
1369, 1336, 1306, 1276, 1246, 1107, 1097, 1015, 995, 924, 863, 768, 751, 733, 690, 
611; MS (70 eV) m/z (%) 280 (M
+
+1, 18), 279 (M
+
, 100), 278 (90), 219 (10), 173 (48), 
144 (18), 114 (17), 77 (14); elemental analysis calcd for C18H17NO2: C 77.40, H 6.13, N 




 Brown oil (183 mg, 
80%); tr 14.06; Rf 0.77 (hexane/EtOAc, 9:1); 
1
H NMR (300 MHz, 
CDCl3) δ 7.28–7.21 (m, 2H), 6.84 (dd, J 8.8, 1.0, 2H), 6.78–6.75 (m, 
1H), 4.00 (t, J 2.1, 2H), 2.94 (s, 3H), 2.16–2.10 (m, 2H), 1.46–1.39 (m, 2H), 1.34–1.23 
(m, 6H), 0.87 (t, J 6.9, 3H); 
13
C NMR (75 MHz, CDCl3) δ 149.6, 129.1, 118.0, 114.4, 
84.6, 75.4, 43.0, 38.6, 31.4, 28.9, 28.6, 22.7, 18.8, 14.2; IR (neat) ν˜ 2954, 2928, 2857, 
1600, 1504, 1466, 1456, 1360, 1330, 1240, 1197, 1111, 1034, 994, 926, 749, 689; MS 
(70 eV) m/z (%) 229 (M
+
, 64), 228 (100), 172 (19), 170 (12), 159 (11), 158 (62), 157 
(17), 156 (12), 145 (11), 144 (90), 143 (15), 132 (76), 131 (11), 120 (17), 107 (20), 106 
(26), 103 (12), 104 (21), 91 (10), 79 (12), 77 (40), 51 (10). 
 
N-(3-Cyclohexylprop-2-yn-1-yl)-N-methylaniline (3af). 
Yellow oil (216 mg, 95%); tr 14.45; Rf 0.77 (hexane/EtOAc, 
9:1); 
1
H NMR (300 MHz, CDCl3) δ 7.28–7.22 (m, 2H), 6.86 (dd, 
J 8.8, 1.0, 2H), 6.81–6.76 (m, 1H), 4.02 (d, J 2.1, 2H,), 2.95 (s, 3H), 2.36–2.30 (m, 1H), 
1.74–1.56 (m, 5H), 1.45–1.27 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 149.9, 129.1, 
118.1, 114.6, 88.8, 74.1, 43.1, 38.6, 32.9, 29.1, 26.0, 24.9; IR (neat) ν˜ 2927, 2852, 
1599, 1504, 1447, 1360, 1338, 1236, 1195, 1111, 994, 926, 748, 689; MS (70 eV) m/z 
(%) 228 (M
+ 
+1, 75), 227 (M
+
, 75), 226 (100), 170 (10), 144 (51), 132 (19), 120 (12), 
106 (13), 104 (11), 91 (11), 79 (12), 77 (28); HRMS (EI) m/z calcd for C16H21N 




N-(7-Chlorohept-2-yn-1-yl)-N-methylaniline (3ag). Orange oil 
(219 mg, 93%); tr 14.60; Rf 0.6 (hexane/EtOAc, 9:1); 
1
H NMR (300 
MHz, CDCl3) δ 7.28–7.22 (m, 2H), 6.86–6.76 (m, 3H), 4.00 (t, J 
2.1, 2H), 3.48 (t, J 6.5, 2H), 2.94 (s, 3H), 2.20–2.16 (m, 2H), 1.83–1.74 (m, 2H), 1.63–
1.53 (m, 2H); 
13
C NMR (75 MHz, CDCl3) δ 149.5, 129.1, 118.1, 114.5, 83.6, 76.3, 44.7, 
43.0, 38.7, 31.5, 26.0, 18.1; IR (neat) ν˜ 3021, 2945, 2861, 1599, 1504, 1454, 1428, 
1361, 1331, 1301, 1240, 1197, 1110, 1033, 994, 925, 751, 690, 669, 649; MS (70 eV) 
m/z (%) 237 (M
+
+2, 23), 236 (M
+
+1, 39), 235 (M
+
, 70), 234 (91), 200 (26), 198 (23), 
172 (11), 170 (13), 159 (13), 158 (50), 157 (36), 156 (20), 145 (11), 144 (77), 143 (19), 
133 (11), 132 (100), 131 (10), 120 (13), 117 (13), 107 (11), 106 (31), 105 (14), 104 
(27), 91 (19), 79 (16), 78 (13), 77 (63), 65 (11), 51 (16); HRMS (EI) m/z calcd for 
C14H18ClN 235.1128, found 235.1122. 
 
Ethyl 4-[methyl(phenyl)amino]but-2-ynoate (3ah). Brown oil 
(187 mg, 86%); tr 13.6; Rf 0.43 (hexane/EtOAc, 9:1); 
1
H NMR 
(300 MHz, CDCl3) δ 7.30–7.25 (m, 2H), 6.85–6.81 (m, 3H), 4.19 (q, J 7.1, 2H), 4.18 (s, 
2H), 2.99 (s, 3H), 1.27 (t, J 7.1, 3H); 
13
C NMR (75 MHz, CDCl3) δ 153.4, 148.7, 129.3, 
118.8, 114.4, 83.5, 76.2, 62.1, 42.7, 38.9, 14.1; IR (neat) ν˜ 2996, 2957, 2927, 2224, 
1707, 1600, 1504, 1364, 1237, 1114, 1054, 1034, 995, 923, 749, 690; MS (70 eV) m/z 
(%) 217 (M
+
, 32), 188 (14), 172 (33), 145 (62), 144 (100), 120 (28), 106 (15), 105 (11), 




(3ai). Orange oil (183 mg, 75%); tr 15.29; Rf 0.46 
(hexane/EtOAc, 7:3); 
1
H NMR (300 MHz, CDCl3) δ 7.28–7.21 
(m, 2H), 6.87–6.84 (m, 2H), 6.79 (ddd, J 8.3, 2.0, 1.0, 1H), 4.07 (s, 2H), 2.95 (s, 3H), 
1.84–1.79 (m, 2H), 1.62–1.33 (m, 9H); 13C NMR (75 MHz, CDCl3) δ 149.4, 129.1, 
118.4, 114.7, 87.9, 79.8, 68.9, 43.1, 40.2, 38.8, 25.2, 23.4; IR (neat) ν˜ 3390, 2931, 





, 89), 242 (100), 186 (13), 172 (11), 146 (30), 145 (16), 144 (83), 132 (57), 
131 (16), 120 (32), 107 (26), 106 (33), 105 (14), 104 (18), 91 (13), 79 (16), 77 (43), 55 







 Yellow oil (205 mg, 87%); tr 15.95 min; Rf 0.54 
(hexane/EtOAc, 9:1); 
1
H NMR (300 MHz, CDCl3):  
7.38–7.35 (m, 3H), 7.27–7.25 (m, 2H), 7.08, 6.84 (AA’XX’ system, 4H), 4.22 (s, 2H), 
2.99 (s, 3H), 2.27 (s, 3H); 
13
C NMR (75 MHz, CDCl3):  147.3, 131.7, 129.6, 128.2, 
123.1, 115.0, 85.1, 84.2, 43.8, 39.0, 20.3; IR (neat) ν˜ 3026, 2918, 2868, 1615, 1518, 
1489, 1333, 1239, 1191, 921, 804, 755, 690 cm
–1










 Yellow oil (270 mg, 90%); tr 17.45 
min ; Rf 0.37 (hexane/EtOAc, 9:1); 
1
H NMR (300 MHz, 
CDCl3):  7.37–7.35 (m, 5H), 7.28, 6.76 (AA’XX’ system, 4H), 7.27 (m, 1H), 4.23 (s, 
2H), 3.01 (s, 3H); 
13
C NMR (75 MHz, CDCl3):  148.2, 131.8, 131.7, 128.2, 122.8, 
115.9, 110.2, 84.4, 84.3, 43.3, 38.8; IR (neat) ν˜ 3013, 2954, 2879, 2820, 2235, 1593, 
1493, 1362, 1338, 1259, 1196, 1111, 1017, 921, 808, 756, 690 cm
–1
; MS (70 eV) m/z 
(%) 301 (M
+
+1, 34), 300 (M
+
, 27), 299 (37), 298 (22), 220 (11), 184 (13), 116 (15), 115 
(100), 89 (10). 
 
Ethyl 4-[methyl(3-phenylprop-2-yn-1-
yl)amino]benzoate (3da). Yellow oil (126 mg, 
43%); tr 19.69 min; Rf 0.63 (hexane/EtOAc, 7:3); 
1
H 
NMR (300 MHz, CDCl3):  7.95, 6.83 (AA’XX’ system, 4H), 7.35–7.28 (m, 2H), 7.27–
7.25 (m, 3H), 4.36–4.29 (q, J 7.1, 4H), 3.12 (s, 3H), 1.37 (t, J 7.1, 3H); 13C NMR (75 
MHz, CDCl3):  166.9, 152.2, 131.7, 131.2, 128.2, 122.6, 118.9, 84.3, 84.1, 60.2, 42.7, 
38.4, 14.5; IR (neat) ν˜ 3011, 2991, 2908, 1698, 1602, 1522, 1276, 1182, 1103, 769, 
757, 693 cm
-1
; MS (70 eV) m/z (%) 294 (M
+
+1, 15), 293 (M
+
, 72), 292 (19), 264 (31), 






yl)amino]benzonitrile (3ea). Yellow oil (123 mg, 
50%); tr 18.42 min; Rf 0.47 (hexane/EtOAc, 7:3); 
1
H 
NMR (300 MHz, CDCl3):  7.52, 6.82 (AA’XX’ system, 4H), 7.39–7.30 (m, 5H), 4.32 
(s, 2H), 3.13 (s, 3H); 
13
C NMR (75 MHz, CDCl3):  151.5, 133.5, 133.4, 131.7, 128.5, 
128.3, 122.4, 112.8, 99.1, 84.5, 83.5, 42.6, 38.4; IR (neat) ν˜ 3063, 2908, 2211, 1604, 
1520, 1372, 1177, 920, 826, 757 cm
–1
; MS (70 eV) m/z (%) 246 (M
+
, 50), 116 (11), 115 





Orange oil (173 mg, 73%); tr 14.99; Rf 0.60 (hexane/EtOAc, 
7:3); 
1
H NMR (300 MHz, CDCl3) δ 7.49–7.45 (m, 2H), 7.36–
7.35 (m, 2H), 7.33–7.24 (m, 6H), 3.64 (s, 2H), 3.52 (s, 2H), 2.41 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 138.4, 131.8, 129.3, 128.3, 128.3, 128.0, 127.2, 123.3, 85.7, 84.4, 60.3, 
45.8, 42.0; IR (neat) ν˜ 3026, 2927, 2829, 2782, 1599, 1489, 1453, 1442, 1364, 1324, 
1123, 1072, 1026, 912, 826, 755, 738, 690; MS (70 eV) m/z (%) 235 (M
+
, 23), 234 (31), 
158 (37), 144 (24), 132 (10), 118 (13), 116 (16), 115 (100), 92 (11), 91 (64). 
 
(R)-N-Methyl-3-phenyl-N-(1-phenylethyl)prop-2-yn-1-amine 
(3ga). Orange oil (175 mg, 70%); tr 15.24; Rf 0.63 
(hexane/EtOAc, 7:3); [α]25 +203º (CHCl3, c 1.00); 
1
H NMR 
(300 MHz, CDCl3): δ 7.52–7.47 (m, 2H), 7.42–7.28 (m, 8H), 3.69, 3.46 (AB system, J 
17.4, 2H), 3.68 (d, J 6.6, 1H), 2.42 (s, 3H), 1.45 (d, J 6.6, 3H); 
13
C NMR (75 MHz, 
CDCl3): δ 144.6, 131.9, 128.5, 128.4, 128.1, 127.6, 127.2, 123.5, 85.6, 84.8, 62.6, 44.9, 
40.1, 21.3; IR (neat) ν˜ 3056, 3035, 2967, 2794, 1604, 1489, 1448, 1322, 1070, 1028, 
754, 699, 690; MS (70 eV) m/z (%) 249 (M
+
, 7), 235 (16), 234 (87), 172 (13), 144 (11), 






Yellow oil (192 mg, 62%); tr 21.69 min; Rf 0.56 (hexane/EtOAc, 9:1); 
1
H NMR (300 MHz, CDCl3):  7.26–7.02 (m, 14H), 5.56 (s, 1H), 3.63–
3.58 (m, 2H), 3.08–2.87 (m, 2H); 13C NMR (75 MHz, CDCl3):  148.5, 
9 
 
134.3, 133.3, 130.7, 128.1, 127.9, 127.0, 126.9, 126.4, 126.2, 125.2, 121.9, 118.6, 
115.6, 87.5, 83.7, 51.3, 42.4, 27.9; IR (neat) ν˜ 3059, 3024, 2957, 2922, 1659, 1596, 
1502, 1489, 1451, 1376, 1338, 1260, 1224, 1199, 1026, 937, 922, 754, 747, 731, 710, 
689 cm
–1
; MS (70 eV) m/z (%) 310 (M
+
+1, 14), 309 (M
+
, 61), 308 (100), 206 (14), 204 





 Yellow oil (216 mg, 95%); tr 14.82 min; Rf 0.37 
(hexane/EtOAc, 9:1); 
1
H NMR (300 MHz, CDCl3):  7.44–
7.42 (m, 2H), 7.30–7.28 (m, 3H), 3.64 (s, 2H), 2.44 (m, 1H), 2.43 (s, 3H), 1.99–1.95 (m, 
2H), 1.82–1.77 (m, 2H), 1.64–1.61 (m, 2H), 1.31–1.19 (m, 4H); 13C NMR (75 MHz, 
CDCl3):  131.7, 128.2, 127.9, 123.4, 85.6, 84.8, 61.1, 43.7, 38.6, 29.8, 26.1, 25.5; IR 
(neat) ν˜ 3009, 2926, 2852, 1489, 1448, 1324, 1041, 754, 690 cm-1; MS (70 eV) m/z (%) 
227 (M
+
, 15), 184 (27), 171 (39), 170 (51), 116 (30), 115 (100), 94 (32), 68 (15). 
 
8-(3-Phenylprop-2-yn-1-yl)-8-azabicyclo[3.2.1]octan-3-one 
(3ja). Yellow oil (120 mg, 50%); tr 16.40 min; Rf 0.55 
(hexane/EtOAc, 1:1); 
1
H NMR (300 MHz, CDCl3):  7.47–7.44 (m, 
2H), 7.32–7.30 (m, 3H), 3.76 (m, 2H), 3.62 (s, 2H), 2.75 (dd, J = 
16.8, 4.4 Hz, 2H), 2.28 (dd, J = 16.8, 1.7 Hz, 2H), 2.17–2.13 (m, 2H), 1.68 (m, 2H); 13C 
NMR (75 MHz, CDCl3):  209.5, 131.8, 128.3, 122.9, 85.8, 84.0, 58.9, 48.55, 41.5, 
27.6 ; IR (neat) ν˜ 3025, 2991, 2957, 2924, 2848, 1715, 1638, 1444, 1421, 1197, 1002, 
759, 717 cm
-1
; MS (70 eV) m/z (%) 239 (M
+
, 9), 238 (11), 210 (11), 197 (42), 196 (12), 
182 (18), 181 (23), 180 (14), 128 (26), 116 (10), 115 (100), 89 (11), 82 (17); HRMS 
(EI) m/z calcd for C16H17NO 239.1310, found 249.1510. 
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Compound 3ea proved to be impossible to purify completely by any means from the starting 









































































































































Figure 6. MS (EI) spectrum of acetone 2,4-dinitrophenylhydrazone. 
